Joseph Walter Strohbach,David Christopher Limburg,John Paul Mathias,Atli Thorarensen,John James Mousseau,Rajiah Aldrin Denny,Christoph Wolfgang Zapf,Ivan Viktorovich Efremov
申请号：
US16506883
公开号：
US10766904B2
申请日:
2019.07.09
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to 5,7-disubstituted-imidazo[5,1-f][1,2,4]triazine-4-amine derivatives, and pharmaceutically acceptable salts thereof. The compounds are potentiators of Cystic Fibrosis Transmembrane conductance Regulator (CFTR). The invention also discloses pharmaceutical compositions comprising the compounds, optionally in combination with additional therapeutic agents, and methods of potentiating, in mammals, including humans, CFTR by administration of the compounds. These compounds are useful for the treatment of cystic fibrosis (CF), asthma, bronchiectasis, chronic obstructive pulmonary disease (COPD), constipation, Diabetes mellitus, dry eye disease, pancreatitis, rhinosinusitis, Sjögren's Syndrome, and other CFTR associated disorders.
